SOD1 Stabilizer (Small Molecule)

Edit / manage →

Amyotrophic lateral sclerosis

PreclinicalActiveSmall moleculeNeurodegenerationMixed· low conf3 evidence-linked claims

Overview

Disease area: Neurodegeneration
Indication: Amyotrophic lateral sclerosisMONDO:0004976
Mechanism of action: Small-molecule stabilization of mutant SOD1 to reduce misfolding and aggregation
Development stage: Preclinical
Institution: Greenfield Institute for Rare Disease
Principal investigators: D. Whitfield, A. Petrov
Targets: SOD1
Pathways: Proteostasis
Trial registry: —

Scientific assessment

1 claims

Mechanistic RationaleModerate
Small-molecule stabilization of mutant SOD1 reduces misfolding and aggregation — a mechanism complementary to allele-selective knockdown, offering a second shot on the same validated target.
datasetMONDO:0004976

Translational assessment

1 claims

BiomarkersModerate
Shares the plasma neurofilament light pharmacodynamic readout used across the SOD1-ALS portfolio, enabling cross-program comparison.
publicationPMID:35921451

Regulatory assessment

0 claims

No evidence linked yet.

Commercial assessment

0 claims

No evidence linked yet.

Execution assessment

1 claims

Operational RisksLimited
Oral small molecule avoids the intrathecal delivery burden of the ASO program but must first demonstrate adequate CNS exposure.
internalrisk-sod1sm

Structured reviews

1 reviews

Mixed· low confInternalDiscovery review2025-05-08

Strengths

Complementary mechanism to the ASO program; oral convenience; validated target.

Weaknesses

Preclinical; CNS exposure and target engagement not yet shown.

Improvement areas

Demonstrate brain target engagement before committing to IND-enabling.

Internal rubric input (reviewer scoring — not a success probability)

Scientific validity

Translational readiness

Regulatory pathway

Commercial potential

Execution strength

Outcome

Active
Preclinical lead optimization; second SOD1 program in the portfolio.2025-05-08

AI brief

flag off · defaultPhase 7

Runtime AI features are flag-gated and disabled by default. Set SIGNAL_LLM_ENABLED=1 (plus a provider key) to enable a grounded, source-cited brief generated from this asset's structured records — with forbidden-phrase and grounding validators enforcing no probability-of-success or buy/sell language.

Evidence tiers and reviewer rubric scores are internal, qualitative inputs — [signal.] surfaces never show a numeric probability of success or buy/sell language.